593 related articles for article (PubMed ID: 33634507)
1. Baseline Modified Glasgow Prognostic Score Associated with Survival in Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors.
Brown JT; Liu Y; Shabto JM; Martini DJ; Ravindranathan D; Hitron EE; Russler GA; Caulfield S; Yantorni LB; Joshi SS; Kissick H; Ogan K; Harris WB; Carthon BC; Kucuk O; Master VA; Bilen MA
Oncologist; 2021 May; 26(5):397-405. PubMed ID: 33634507
[TBL] [Abstract][Full Text] [Related]
2. Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors.
Brown JT; Liu Y; Shabto JM; Martini D; Ravindranathan D; Hitron EE; Russler GA; Caulfield S; Yantorni L; Joshi SS; Kissick H; Ogan K; Nazha B; Carthon BC; Kucuk O; Harris WB; Master VA; Bilen MA
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326170
[TBL] [Abstract][Full Text] [Related]
3. A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors.
Khaki AR; Li A; Diamantopoulos LN; Miller NJ; Carril-Ajuria L; Castellano D; De Kouchkovsky I; Koshkin V; Park J; Alva A; Bilen MA; Stewart T; Santos V; Agarwal N; Jain J; Zakharia Y; Morales-Barrera R; Devitt M; Nelson A; Hoimes CJ; Shreck E; Gartrell BA; Sankin A; Tripathi A; Zakopoulou R; Bamias A; Rodriguez-Vida A; Drakaki A; Liu S; Kumar V; Lythgoe MP; Pinato DJ; Murgic J; Fröbe A; Joshi M; Isaacsson Velho P; Hahn N; Alonso Buznego L; Duran I; Moses M; Barata P; Galsky MD; Sonpavde G; Yu EY; Shankaran V; Lyman GH; Grivas P
Eur Urol Oncol; 2021 Jun; 4(3):464-472. PubMed ID: 33423945
[TBL] [Abstract][Full Text] [Related]
4. Body Composition as an Independent Predictive and Prognostic Biomarker in Advanced Urothelial Carcinoma Patients Treated with Immune Checkpoint Inhibitors.
Martini DJ; Shabto JM; Goyal S; Liu Y; Olsen TA; Evans ST; Magod BL; Ravindranathan D; Brown JT; Yantorni L; Russler GA; Caulfield S; Goldman JM; Nazha B; Joshi SS; Kissick HT; Ogan KE; Harris WB; Kucuk O; Carthon BC; Master VA; Bilen MA
Oncologist; 2021 Dec; 26(12):1017-1025. PubMed ID: 34342095
[TBL] [Abstract][Full Text] [Related]
5. Modified Glasgow Prognostic Score 2 as a Prognostic Marker in Patients With Metastatic Urothelial Carcinoma.
Nagai T; Naiki T; Isobe T; Sugiyama Y; Etani T; Iida K; Nozaki S; Noda Y; Shimizu N; Tasaki Y; Mimura Y; Banno R; Kubota H; Hamamoto S; Kawai N; Yasui T
In Vivo; 2021; 35(5):2793-2800. PubMed ID: 34410970
[TBL] [Abstract][Full Text] [Related]
6. On-treatment Modified Glasgow Prognostic Score Provides Predictive Information Complementary to Radiological Staging in Metastatic Urothelial Carcinoma on Immunotherapy.
Saal J; Grünwald V; Bald T; Ritter M; Brossart P; Tomita Y; Hartmann A; Hölzel M; Eckstein M; Klümper N
Eur Urol Oncol; 2024 Jun; 7(3):328-331. PubMed ID: 37996277
[TBL] [Abstract][Full Text] [Related]
7. Prognostic model in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitors after platinum failure.
Park JH; Park I; Kim IH; Hur JY; Hwang I; Kim C; Kim HJ; Maeng CH; Park K; Lee MY; Lee HJ; Jung JY; Keam B; Park SH; Lee JL
Curr Probl Cancer; 2022 Jun; 46(3):100848. PubMed ID: 35344842
[TBL] [Abstract][Full Text] [Related]
8. A comprehensive analysis of Glasgow Prognostic Score (GPS)/the modified Glasgow Prognostic Score (mGPS) on immune checkpoint inhibitor efficacy among patients with advanced cancer.
Zhang Y; Chen S; Chen H; Li W
Cancer Med; 2023 Jan; 12(1):38-48. PubMed ID: 35702873
[TBL] [Abstract][Full Text] [Related]
9. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
10. Role of Bone Metastases in Patients Receiving Immunotherapy for Pre-Treated Urothelial Carcinoma: The Multicentre, Retrospective Meet-URO-1 Bone Study.
Raggi D; Giannatempo P; Marandino L; Pierantoni F; Maruzzo M; Lipari H; Banna GL; De Giorgi U; Casadei C; Naglieri E; Buti S; Bersanelli M; Stellato M; Santini D; Vignani F; Roviello G; Veccia A; Caffo O; Losanno T; Calabrò F; Mucciarini C; Pignata S; Necchi A; Maio MD;
Clin Genitourin Cancer; 2022 Apr; 20(2):155-164. PubMed ID: 35000876
[TBL] [Abstract][Full Text] [Related]
11. Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysis.
Rizzo A; Mollica V; Massari F
Eur Urol Focus; 2022 Jan; 8(1):152-159. PubMed ID: 33516645
[TBL] [Abstract][Full Text] [Related]
12. Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
Maiorano BA; Di Maio M; Cerbone L; Maiello E; Procopio G; Roviello G;
JAMA Netw Open; 2024 Mar; 7(3):e241215. PubMed ID: 38446479
[TBL] [Abstract][Full Text] [Related]
13. Sex hormones influence survival of patients with metastatic urothelial carcinoma undergoing immune checkpoint therapy.
Lindner AK; Lackner F; Tymoszuk P; Barth DA; Seeber A; Kocher F; Toth B; Hochleitner M; Pichler M; Pichler R
Biol Sex Differ; 2023 Jun; 14(1):38. PubMed ID: 37277835
[TBL] [Abstract][Full Text] [Related]
14. First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis.
Mori K; Pradere B; Moschini M; Mostafaei H; Laukhtina E; Schuettfort VM; Sari Motlagh R; Soria F; Teoh JYC; Egawa S; Powles T; Shariat SF;
Eur J Cancer; 2021 Jul; 151():35-48. PubMed ID: 33962359
[TBL] [Abstract][Full Text] [Related]
15. Clinical utility of pretreatment Glasgow prognostic score in non-small-cell lung cancer patients treated with immune checkpoint inhibitors.
Takamori S; Takada K; Shimokawa M; Matsubara T; Fujishita T; Ito K; Toyozawa R; Yamaguchi M; Okamoto T; Yoneshima Y; Tanaka K; Okamoto I; Tagawa T; Mori M
Lung Cancer; 2021 Feb; 152():27-33. PubMed ID: 33341085
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of modified Glasgow Prognostic Score in non-muscle-invasive bladder cancer.
Kimura S; D' Andrea D; Soria F; Foerster B; Abufaraj M; Vartolomei MD; Iwata T; Karakiewicz PI; Rink M; Gust KM; Egawa S; Shariat SF
Urol Oncol; 2019 Mar; 37(3):179.e19-179.e28. PubMed ID: 30580906
[TBL] [Abstract][Full Text] [Related]
17. Predictors of Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Urothelial Carcinoma: A Systematic Review and Meta-Analysis.
Ferro M; Crocetto F; Tataru S; Barone B; Dolce P; Lucarelli G; Sonpavde G; Musi G; Antonelli A; Veccia A; Terracciano D; Busetto GM; Del Giudice F; Marchioni M; Schips L; Porpiglia F; Fiori C; Carrieri G; Lasorsa F; Verde A; Scafuri L; Buonerba C; Di Lorenzo G
Clin Genitourin Cancer; 2023 Oct; 21(5):574-583. PubMed ID: 37419854
[TBL] [Abstract][Full Text] [Related]
18. The 27-gene IO score is associated with efficacy of PD-1/L1 inhibitors independent of FGFR expression in a real-world metastatic urothelial carcinoma cohort.
Nielsen TJ; Varga MG; Cronister CT; Ring BZ; Seitz RS; Ross DT; Schweitzer BL; McGregor K
Cancer Immunol Immunother; 2023 Jul; 72(7):2075-2086. PubMed ID: 36806983
[TBL] [Abstract][Full Text] [Related]
19. Impact of modified Glasgow prognostic score on predicting prognosis and modification of risk model for patients with metastatic renal cell carcinoma treated with first line tyrosine kinase inhibitor.
Yukihiro K; Teishima J; Goto K; Aoki G; Sekino Y; Hayashi T; Hasegawa Y; Mita K; Kato M; Kajiwara M; Shigeta M; Maruyama S; Kadonishi Y; Fujiwara S; Hinata N
Urol Oncol; 2022 Oct; 40(10):455.e11-455.e18. PubMed ID: 35851184
[TBL] [Abstract][Full Text] [Related]
20. First-line Immune Checkpoint Inhibitor Versus Immune Checkpoint Inhibitor With Chemotherapy for Cisplatin-ineligible Metastatic Urothelial Carcinoma: Evidence From a Real-world, Multicenter Analysis.
Lin CT; Su PJ; Huang SY; Wu CC; Wang HJ; Cheng YT; Luo HL; Chen CH; Liu TT; Huang CC; Su YL
J Immunother; 2022 Nov-Dec 01; 45(9):407-414. PubMed ID: 36121316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
